Literature DB >> 3129795

A study on immunodiagnosis of gnathostomiasis by ELISA and double diffusion with special reference to the antigenicity of Gnathostoma doloresi.

I Tada1, T Araki, H Matsuda, K Araki, H Akahane, T Mimori.   

Abstract

In order to diagnose gnathostomiasis immunologically, Gnathostoma doloresi was evaluated for the antigenicity in comparison with G. hispidum which was recently reported in Japan by using micro-ELISA. The study revealed that G. doloresi can be used as the alternate source of antigen in the test. A significant increase of specific IgG antibodies was seen in 22 (73.3%) out of 30 gnathostomiasis cases. Although double diffusion was slightly less sensitive than ELISA, it was considered more specific than the latter method.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3129795

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  3 in total

1.  Characterization of the humoral immune response against Gnathostoma binucleatum in patients clinically diagnosed with gnathostomiasis.

Authors:  José Francisco Zambrano-Zaragoza; Ma de Jesús Durán-Avelar; Maud Messina-Robles; Norberto Vibanco-Pérez
Journal:  Am J Trop Med Hyg       Date:  2012-06       Impact factor: 2.345

2.  Identification of immunodominant peptides from Gnathostoma binucleatum.

Authors:  Samuel Campista-León; Francisco Delgado-Vargas; Abraham Landa; Kaethe Willms; Hector Samuel López-Moreno; Guillermo Mendoza-Hernández; Julian Ríos-Sicairos; Angel Noel Bojórquez-Contreras; Sylvia Páz Díaz-Camacho
Journal:  Am J Trop Med Hyg       Date:  2012-09-04       Impact factor: 2.345

3.  A serologically diagnosed human case of cutaneous larva migrans caused by Ancylostoma caninum.

Authors:  In-Ho Kwon; Hyung-Su Kim; Jong-Hee Lee; Min-Ho Choi; Jong-Yil Chai; Fukumi Nakamura-Uchiyama; Yukifumi Nawa; Kwang-Hyun Cho
Journal:  Korean J Parasitol       Date:  2003-12       Impact factor: 1.341

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.